Cargando…
Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
Triple negative breast cancer (TNBC) is a subtype of breast cancer, with estrogen receptor, human epidermal growth factor receptor 2 and progesterone receptor negative. TNBC is characterized by high heterogeneity, high rates of metastasis, poor prognosis, and lack of therapeutic targets. Now the tre...
Autores principales: | Yang, Ruoning, Li, Yueyi, Wang, Hang, Qin, Taolin, Yin, Xiaomeng, Ma, Xuelei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894518/ https://www.ncbi.nlm.nih.gov/pubmed/35243562 http://dx.doi.org/10.1186/s43556-022-00071-6 |
Ejemplares similares
-
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020) -
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022) -
Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022) -
Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021) -
Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)